Liontrust Investment Partners LLP Has $78.80 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Liontrust Investment Partners LLP raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3,055.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 187,629 shares of the company’s stock after acquiring an additional 181,682 shares during the quarter. Liontrust Investment Partners LLP owned approximately 0.23% of IDEXX Laboratories worth $78,795,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in shares of IDEXX Laboratories by 59,810.7% during the 1st quarter. GAMMA Investing LLC now owns 918,431 shares of the company’s stock worth $3,856,950,000 after acquiring an additional 916,898 shares during the last quarter. Nuveen LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at $179,784,000. Principal Financial Group Inc. lifted its position in shares of IDEXX Laboratories by 58.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after acquiring an additional 414,802 shares during the period. Alyeska Investment Group L.P. bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $156,412,000. Finally, BNP Paribas Financial Markets lifted its position in shares of IDEXX Laboratories by 221.3% during the 4th quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company’s stock valued at $182,459,000 after acquiring an additional 303,966 shares during the period. 87.84% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total value of $18,491,734.80. Following the completion of the transaction, the chief executive officer owned 83,311 shares of the company’s stock, valued at $52,650,885.78. This represents a 25.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sharon E. Underberg sold 5,450 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the transaction, the executive vice president directly owned 6,156 shares of the company’s stock, valued at approximately $4,011,249.60. The trade was a 46.96% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,176 shares of company stock worth $34,060,678. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $653.95 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The company has a market cap of $52.32 billion, a P/E ratio of 54.45, a P/E/G ratio of 4.30 and a beta of 1.49. The business has a fifty day simple moving average of $555.92 and a 200 day simple moving average of $485.51.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the company earned $2.44 EPS. IDEXX Laboratories’s revenue for the quarter was up 10.6% on a year-over-year basis. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. BTIG Research upped their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research report on Tuesday, August 5th. Piper Sandler reiterated a “neutral” rating and set a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They set a “buy” rating and a $625.00 target price for the company. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, July 12th. Finally, JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the stock an “overweight” rating in a research report on Monday, August 4th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $644.67.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.